Organization
Banner MD Anderson Cancer Center
16 abstracts
Abstract
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.Org: Fred Hutchinson Cancer Center, Duke University Health System, Center for Lymphoma, University of Chicago Medical Center, Chicago, IL, Banner MD Anderson Cancer Center,
Abstract
Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.Org: Vanderbilt University Cancer Center, University of Amsterdam, Stanford University School of Medicine, Washington University School of Medicine, Hematology Department, Institut Català d'Oncologia-Hospitalet,
Abstract
HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,
Abstract
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).Org: Mayo Clinic, NYU Langone Health, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, University of California Irvine,
Abstract
Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Johns Hopkins Medicine, University of Chicago, Nanobiotix,
Abstract
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Humanitas University, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki University Hospital Comprehensive Cancer Center, Semmelweis University,
Abstract
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.Org: Banner MD Anderson Cancer Center, Massachusetts General Hospital, Southern Oncology Clinical Research Unit Pty Ltd., Alfred Hospital and Monash University, Mary Crowley Cancer Research Center,
Abstract
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.Org: Sarah Cannon Research Institute and Sidney Kimmel Cancer Center, Thomas Jefferson University, Thomas Jefferson University, START Midwest, Grand Rapids, MI, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, START San Antonio,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
Differences in perceptions and use of remote patient monitoring technology in rural cancer programs.Org: Penn State Health Milton S. Hershey Medical Center, Hershey, PA, Association of Community Cancer Centers (ACCC), Rockville, MD, Rockville, MD, Rhizome, LLC,
Abstract
Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.Org: Mayo Clinic Florida, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Karmanos Cancer Institute, Hoag Family Cancer Institute and University of Southern California,
Abstract
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.Org: University of Southern California Norris Comprehensive Cancer Center, MD Anderson Cancer Center, University Hospitals Gasthuisberg/Leuven and KU Leuven, Hospital Universitario Virgen del Rocio, Westmead Hospital,
Abstract
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Moffitt Cancer Center, Johns Hopkins Medicine, Nanobiotix,
Abstract
Tumor treating fields (TTFields) therapy skin safety and prevention strategy using a fractionated schema protocol (3-days on/1-day off), effect on skin adverse events.Org: Banner MD Anderson Cancer Center, Geisinger Health System Department of Pathology, Brown University - Lifespan Cancer Institute,
Abstract
Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study.Org: Banner MD Anderson Cancer Center, Mary Crowley Cancer Research Center, Virginia Health Specialists, Fairfax, VA, Prisma Health Cancer Institute, ImmVira Co., Limited,
Abstract
Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).Org: Queen Elizabeth II Health Sciences Centre and Dalhousie University, David Geffen School of Medicine at UCLA, Banner MD Anderson Cancer Center, Division of Hematology/Oncology, Columbia University, Clalit Health Services, Ha’Emek Medical Center,